Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Bought by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. raised its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 211.7% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 215,890 shares of the biopharmaceutical company's stock after buying an additional 146,617 shares during the quarter. Assenagon Asset Management S.A. owned about 0.23% of Ultragenyx Pharmaceutical worth $7,817,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of RARE. GAMMA Investing LLC lifted its position in shares of Ultragenyx Pharmaceutical by 76.2% during the first quarter. GAMMA Investing LLC now owns 747 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 323 shares in the last quarter. Smartleaf Asset Management LLC lifted its position in shares of Ultragenyx Pharmaceutical by 259.5% during the fourth quarter. Smartleaf Asset Management LLC now owns 683 shares of the biopharmaceutical company's stock worth $29,000 after purchasing an additional 493 shares in the last quarter. Aster Capital Management DIFC Ltd acquired a new stake in shares of Ultragenyx Pharmaceutical during the fourth quarter worth about $35,000. Human Investing LLC acquired a new stake in shares of Ultragenyx Pharmaceutical during the fourth quarter worth about $42,000. Finally, Van ECK Associates Corp lifted its position in shares of Ultragenyx Pharmaceutical by 18.4% during the fourth quarter. Van ECK Associates Corp now owns 1,760 shares of the biopharmaceutical company's stock worth $74,000 after purchasing an additional 273 shares in the last quarter. Institutional investors and hedge funds own 97.67% of the company's stock.

Analyst Ratings Changes

A number of research firms recently weighed in on RARE. William Blair began coverage on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, May 28th. They set an "outperform" rating and a $65.00 target price on the stock. Morgan Stanley upped their target price on shares of Ultragenyx Pharmaceutical from $64.00 to $65.00 and gave the stock an "overweight" rating in a research note on Friday, May 9th. JPMorgan Chase & Co. increased their price target on shares of Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the company an "overweight" rating in a research note on Thursday, March 27th. Canaccord Genuity Group increased their price target on shares of Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the company a "buy" rating in a research note on Tuesday, February 18th. Finally, Piper Sandler dropped their price target on shares of Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an "overweight" rating on the stock in a research note on Monday, March 17th. One research analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $88.77.

Ultragenyx Pharmaceutical Stock Performance

Ultragenyx Pharmaceutical stock opened at $37.49 on Friday. Ultragenyx Pharmaceutical Inc. has a one year low of $29.59 and a one year high of $60.37. The business has a fifty day moving average of $36.04 and a two-hundred day moving average of $40.03. The company has a market cap of $3.54 billion, a P/E ratio of -5.91 and a beta of 0.25.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last released its earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($1.57) EPS for the quarter, missing analysts' consensus estimates of ($1.54) by ($0.03). Ultragenyx Pharmaceutical had a negative net margin of 101.60% and a negative return on equity of 193.80%. The business had revenue of $139.29 million during the quarter, compared to analyst estimates of $145.98 million. During the same period last year, the business posted ($2.03) EPS. Ultragenyx Pharmaceutical's revenue was up 28.0% compared to the same quarter last year. Sell-side analysts predict that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current year.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.